BioSpace News Archive

A panel of cardiologists, engineers, and other experts have given SentiAR, Inc.’s augmented reality (AR) platform an exceptional peer review, leading the National Institutes for Health (NIH) to award SentiAR a prestigious research grant to advance its work to revolutionize the operating room with AR software designed to improve visualization in cardiac surgeries and other interventional procedures.

The REFLECT study reported on in the paper was a multicenter, open-label, randomized, global Phase III study comparing the efficacy and safety of lenvatinib versus sorafenib, a standard treatment for advanced hepatocellular carcinoma, as a first-line treatment in patients with unresectable HCC.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company’s New Drug Application for lorlatinib.

Saama Technologies, Inc., a leading clinical analytics company, and Citeline, Inc., part of Informa Pharma Intelligence’s suite of pharmaceutical and biomedical research and analysis solutions, unveiled a strategic partnership today that will disrupt and advance the existing clinical trial landscape.

Visterra announced that new preclinical results with VIS513, its novel monoclonal antibody in development for the treatment of dengue, were published online in the journal PLOS Neglected Tropical Diseases (Y. Budigi et al., PLoS Negl Trop Dis 12(2): e0006209. https://doi.org/10.1371/journal.pntd.0006209).

The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and finally “Events and Webcasts” and will be archived there for future reference.

Neptune and Tetra Bio-Pharma announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.

Under the terms of the agreement, Horizon has licensed to the Partner a novel cell line engineering technology as well as non-exclusive rights to Horizon’s proprietary Helitron transposon gene editing technology for an undisclosed financial consideration.

Colorectal cancer is the third most common cancer and second leading cause of cancer death in the United States.

Applications of the technique range from oncology and undiagnosed disease research, to retrospective analysis of clinical trials.